Radiology · 1999 · 127 citations · 33 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyMetastasisBreast Cancer ImagingBreast ImagingMetastatic Breast CancerTumor ImagingAxillary Lymph Node MetastasisAxillary Node ImagingBreast Imaging FindingsBreast Lesion DiagnosisMagnetic ResonanceMagnetic Resonance Imaging Lesion EvaluationMetastatic Tumor DetectionPositron Emission Tomography Detection
PURPOSE: To assess the performance and potential clinical effects of combined 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and magnetic resonance (MR) imaging of the axilla and brachial plexus in patients suspected of having local-regional breast cancer metastases. MATERIALS AND METHODS: Upper-body FDG PET and axillary and supraclavicular MR imaging were performed in 10 patients (age range, 45-71 years) with clinical findings suggestive of breast cancer metastases. Medical records were reviewed retrospectively. Imaging findings were correlated with clinical data and follow-up findings in all patients. Surgical findings were available in four patients. RESULTS: Nine patients had local-regional breast cancer metastases. MR imaging was diagnostic for tumor in five patients and was indeterminate in four patients with axillary or chest wall metastases. With FDG PET, metastatic tumor was positively identified in all nine patients. MR imaging was useful for determining the relationship of metastatic tumor to axillary and supraclavicular neurovascular structures. FDG PET helped confirm metastases in patients with indeterminate MR imaging findings and depicted unsuspected metastases outside the axilla. CONCLUSION: MR imaging and FDG PET are complementary in detecting and characterizing local-regional breast cancer metastases. Combined FDG PET and MR imaging provide useful treatment-planning data for patients clinically suspected of having recurrent axillary or supraclavicular breast cancer.
33
The applications of PET in clinical oncology.
Ludwig G. Strauss, Peter S. Conti · PubMed · 1991 · 855 citations
Medicine, Nuclear Medicine, Oncology +17
Performance characteristics of a whole-body PET scanner.
Timothy R. DeGrado, Timothy G. Turkington, John Williams et al. · PubMed · 1994 · 516 citations
Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Lee P. Adler, Joseph P. Crowe, Nadia Al‐Kaisi et al. · Radiology · 1993 · 374 citations